Antithyroid drugs

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
All congenital malformations (majors, minors, majors and minors, or unspecified)1.23 [1.09, 1.38]20%13 studies250,16520,031not evaluable NA
Major congenital malformations1.30 [0.94, 1.79]0%7 studies2683,483not evaluable NA
Urinary malformations1.69 [1.10, 2.61]58%3 studies17,72915,800not evaluable NA
Genital anomalies1.17 [0.96, 1.41]0%3 studies25,84815,800not evaluable NA
Limb defects1.08 [0.82, 1.41]61%3 studies74,80015,800not evaluable NA
Respiratory system anomalies1.16 [0.67, 2.01]71%3 studies16,03715,800not evaluable NA
Congenital heart defects1.33 [0.98, 1.79]71%3 studies77,71315,800not evaluable NA
Ear, face and neck anomalies1.50 [0.59, 3.82]0%2 studies9172,909not evaluable NA
Eye defects1.39 [0.70, 2.74]0%2 studies2,4932,909not evaluable NA
Severe congenital heart defect0.63 [0.04, 9.47]71%2 studies7392,757not evaluable NA
Abdominal wall defects3.37 [1.63, 6.96]0%2 studies9332,909not evaluable NA
Ano-rectal atresia and stenosis1.41 [0.29, 6.91]46%3 studies1,0573,208not evaluable NA
Cardiac septal defects1.87 [1.14, 3.06]-1 study1,097not evaluable NA
Craniosynostosis1.53 [0.43, 5.51]0%3 studies1,5372,684not evaluable NA
Digestive system anomalies1.36 [1.08, 1.71]0%2 studies12,07013,337not evaluable NA
Nervous system anomalies1.45 [1.06, 2.00]0%2 studies5,88413,337not evaluable NA
Omphalocele3.02 [0.56, 16.34]66%3 studies1653,321not evaluable NA
Syndromes and chromosomal abnormalities0.88 [0.34, 2.27]26%2 studies5,5572,909not evaluable NA
Aortic valve atresia/stenosis1.75 [0.07, 44.39]71%2 studies4942,643not evaluable NA
Atresia of bile ducts0.48 [0.06, 3.92]0%2 studies33,194not evaluable NA
Carbimazole embryopathy5.24 [0.80, 34.53]50%2 studies2,04813,095not evaluable NA
Choanal atresia12.25 [5.02, 29.88]0%2 studies119139not evaluable NA
Congenital hydronephrosis2.60 [0.62, 10.95]0%2 studies103,194not evaluable NA
Hypospadias1.85 [0.27, 12.64]0%2 studies43,194not evaluable NA
Oro-facial clefts1.22 [0.78, 1.90]0%2 studies3,46713,455not evaluable NA
Pulmonary valve stenosis1.72 [0.45, 6.64]0%2 studies1,519577not evaluable NA
Situs inversus16.80 [2.99, 94.32]35%2 studies272,757not evaluable NA
Ventricular septal defect0.99 [0.51, 1.91]0%2 studies373,194not evaluable NA
Coarctation of aorta3.99 [1.02, 15.54]-1 study1,13714not evaluable NA
Microcephaly / Small head circumference for gestational age--0 study
26 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Preterm (< 37 weeks)0.95 [0.78, 1.16]3%11 studies6392,427not evaluable NA
Low birth weight (< 2500g)1.34 [0.78, 2.32]55%4 studies3071,324not evaluable NA
Small for gestational age (weight)1.06 [0.86, 1.30]0%3 studies5601,400not evaluable NA
Small for gestational age (length)--0 study
2 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Maternal liver disorder / failure during pregnancy--0 study
Preeclampsia1.13 [0.13, 10.01]0%2 studies4310not evaluable NA
2 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Goiter2.03 [0.18, 23.21]57%3 studies27170not evaluable NA
Hypothyroidism (fetal/neonatal)2.54 [0.51, 12.61]6%4 studies11346not evaluable NA
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)3.27 [0.40, 26.43]40%3 studies15204not evaluable NA
Hearing loss / Auditory deficit0.56 [0.08, 3.80]5%2 studies53,194not evaluable NA
Neonatal hyperthyrotropinemia3.02 [1.04, 8.78]-1 study18111not evaluable NA
Child/Infant death (> 28 days of life)--0 study
2 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Early intrauterine death (< 22 weeks)1.89 [0.68, 5.24]85%4 studies5803,399not evaluable NA
Intrauterine deaths (as a whole or unspecified)1.41 [0.88, 2.25]0%5 studies86435not evaluable NA
Elective termination of pregnancy1.97 [1.17, 3.33]0%3 studies993,295not evaluable NA
Late intrauterine deaths (> 22 weeks)0.20 [0.01, 6.47]74%2 studies9167not evaluable NA
Perinatal death0.76 [0.36, 1.56]0%3 studies293,350not evaluable NA
Ectopic pregnancy--0 study

Neuro-developmental disorders
Adverse outcome OR 95%CII2k No. casesNo. exposedpublication biasROB
Neuro-developmental disorders (as a whole)5.34 [2.17, 13.10]-1 study69220not evaluable NA

- About - Master protocol - Browse exposition - RSS - Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons